Xueying Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xueying Zheng has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
Guoyou Qin
Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, People’s Republic of China
5 shared publications- Guoyou Qin
Fudan University
4 shared publications - Xiling Wang
School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Xuhui District, Shanghai, 200231, China
4 shared publications Zhenyu Wu
Department of Biostatistics, School of Public Health, Fudan University
4 shared publicationsChen Huang
Department of Biostatistics, NHC Key Laboratory for Health Technology Assessment, Key Laboratory of Public Health Safety of Ministry of Education, School of Public Health, Fudan University, Shanghai 200032 China
3 shared publicationsRuilang Lin
Affiliation Key Laboratory of Public Health Safety of Ministry of Education, NHC Key Laboratory for Health Technology Assessment, School of Public Health, Fudan University, Shanghai, China
3 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Age-specific risk and clustering patterns of metabolically unhealthy status associated with obstructive coronary artery disease in obese and non-obese adults
- 18 August 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Open AccessAge-specific risk and clustering patterns of metabolically unhealthy status associated with obstructive coronary artery disease in obese and non-obese adults
- 16 April 2026
- Published by Wiley in Statistics in Medicine
- Vol. 45 (8-9) , e70548
Sensitivity Analysis for Unmeasured Confounding in Causal Mediation Analysis With Survival Outcome
The validity of mediation analysis critically depends on the assumption of no unmeasured confounding, which is typically evaluated through sensitivity analysis. However, existing sensitivity analysis methods for mediation analysis with survival outcomes often rely on the rare outcome assumption and neglect the relationship between exposure and unmeasured confounding. To address this challenge, we developed a sensitivity analysis approach to assess the robustness of mediation results. Specifically, it can assess sensitivity to both mediator‐outcome confounding and confounding involving the exposure in observational studies. Our method innovatively generates a simulated unmeasured confounder from its conditional distribution, constructed through sensitivity parameters such as regression coefficients linking the outcome, mediator, and exposure to the unmeasured confounder. Then the sensitivity of mediation analysis can be evaluated by comparing the results before and after adjusting for the simulated unmeasured confounder. A three‐dimensional visualization tool was developed to visualize the sensitivity of mediation analysis results. We validated our methodology on simulated datasets and further applied it to a real dataset from the China Health and Nutrition Survey (CHNS) to investigate the relationship between obesity and stroke mediated by hypertension. An R package “medsenssurv” has also been developed to facilitate implementation of our proposed method ( https://github.com/Guo‐yi‐y/medsenssurv ).
- 16 April 2026
- Published by Wiley in Statistics in Medicine
- Vol. 45 (8-9) , e70548
Sensitivity Analysis for Unmeasured Confounding in Causal Mediation Analysis With Survival Outcome
The validity of mediation analysis critically depends on the assumption of no unmeasured confounding, which is typically evaluated through sensitivity analysis. However, existing sensitivity analysis methods for mediation analysis with survival outcomes often rely on the rare outcome assumption and neglect the relationship between exposure and unmeasured confounding. To address this challenge, we developed a sensitivity analysis approach to assess the robustness of mediation results. Specifically, it can assess sensitivity to both mediator‐outcome confounding and confounding involving the exposure in observational studies. Our method innovatively generates a simulated unmeasured confounder from its conditional distribution, constructed through sensitivity parameters such as regression coefficients linking the outcome, mediator, and exposure to the unmeasured confounder. Then the sensitivity of mediation analysis can be evaluated by comparing the results before and after adjusting for the simulated unmeasured confounder. A three‐dimensional visualization tool was developed to visualize the sensitivity of mediation analysis results. We validated our methodology on simulated datasets and further applied it to a real dataset from the China Health and Nutrition Survey (CHNS) to investigate the relationship between obesity and stroke mediated by hypertension. An R package “medsenssurv” has also been developed to facilitate implementation of our proposed method ( https://github.com/Guo‐yi‐y/medsenssurv ).
- Open Access
- 6 March 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (3) , e0344566
Association of intraindividual differences in estimated glomerular filtration rates based on cystatin C and creatinine with dementia: A cohort study of the UK Biobank
Background: Dementia is a leading cause of cognitive decline, with Alzheimer’s disease (AD) and vascular dementia (VaD) being the most common subtypes. The intraindividual difference between the estimated glomerular filtration rate based on cystatin C and creatinine (eGFR diff ) may serve as an indicator of the overall health status of an individual. However, the relationships between the eGFR diff and dementia risk, dementia subtypes, dementia-related neuroimaging changes, and cognitive functions remain unclear. Methods: This study analysed data from over 450,000 participants in the UK Biobank who were followed for up to 15 years. The estimated glomerular filtration rate based on cystatin C (eGFR cys ) and creatinine (eGFR cr ) was calculated using the CKD-EPI equation, and eGFR diff was defined as the difference between these values (eGFR diff = eGFR cys − eGFR cr ). Multivariate Cox regression models were used to evaluate the associations between the eGFR diff and all-cause dementia (ACD), AD, and VaD, whereas cross-sectional analysis were used to examine the relationship among the eGFR diff , dementia-related neuroimaging changes, and cognitive functions. Results: Over a median follow-up of 13.5 years, 8,710 participants developed dementia, including 3,910 with AD and 1,893 with VaD. Each one standard deviation increase in eGFR diff was associated with a reduced risk of dementia, with hazard ratios (95% confidence intervals) of 0.92 (0.90–0.94) for ACD, 0.94 (0.91–0.98) for AD, and 0.90 (0.85–0.94) for VaD. A negative eGFR diff was associated with adverse neuroimaging changes, including lower total brain and gray matter volumes and higher white matter hyperintensities. Additionally, a negative eGFR diff was associated with poorer performance across multiple cognitive domains. Conclusion: A negative eGFR diff was associated with an increased risk of dementia, adverse neuroimaging outcomes, and cognitive decline. These findings suggest that the eGFR diff might be considered a potential associative indicator for dementia and cognitive impairment, suggesting potential clinical value in risk assessment and early intervention strategies.
- 6 March 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (3) , e0344566
Open AccessAssociation of intraindividual differences in estimated glomerular filtration rates based on cystatin C and creatinine with dementia: A cohort study of the UK Biobank
Background: Dementia is a leading cause of cognitive decline, with Alzheimer’s disease (AD) and vascular dementia (VaD) being the most common subtypes. The intraindividual difference between the estimated glomerular filtration rate based on cystatin C and creatinine (eGFR diff ) may serve as an indicator of the overall health status of an individual. However, the relationships between the eGFR diff and dementia risk, dementia subtypes, dementia-related neuroimaging changes, and cognitive functions remain unclear. Methods: This study analysed data from over 450,000 participants in the UK Biobank who were followed for up to 15 years. The estimated glomerular filtration rate based on cystatin C (eGFR cys ) and creatinine (eGFR cr ) was calculated using the CKD-EPI equation, and eGFR diff was defined as the difference between these values (eGFR diff = eGFR cys − eGFR cr ). Multivariate Cox regression models were used to evaluate the associations between the eGFR diff and all-cause dementia (ACD), AD, and VaD, whereas cross-sectional analysis were used to examine the relationship among the eGFR diff , dementia-related neuroimaging changes, and cognitive functions. Results: Over a median follow-up of 13.5 years, 8,710 participants developed dementia, including 3,910 with AD and 1,893 with VaD. Each one standard deviation increase in eGFR diff was associated with a reduced risk of dementia, with hazard ratios (95% confidence intervals) of 0.92 (0.90–0.94) for ACD, 0.94 (0.91–0.98) for AD, and 0.90 (0.85–0.94) for VaD. A negative eGFR diff was associated with adverse neuroimaging changes, including lower total brain and gray matter volumes and higher white matter hyperintensities. Additionally, a negative eGFR diff was associated with poorer performance across multiple cognitive domains. Conclusion: A negative eGFR diff was associated with an increased risk of dementia, adverse neuroimaging outcomes, and cognitive decline. These findings suggest that the eGFR diff might be considered a potential associative indicator for dementia and cognitive impairment, suggesting potential clinical value in risk assessment and early intervention strategies.
- Open Access
- 7 July 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (7) , 390
Trajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical Trial
Background: A single measurement or a summary of a limited number of measurements of CA125 was considered in the prediction of clinical outcomes for patients with ovarian cancer. We aimed to identify the classes of patients with advanced ovarian cancer based on their CA125 trajectory and to investigate the heterogeneity of clinical outcomes among the patients in the different classes. Methods: CA125 trajectory classes were identified by latent-class mixed models based on values collected within 3 and 6 months post-treatment for 819 women with advanced ovarian cancer enrolled in a randomized trial. Results: Based on their CA125 values during the first 6 months of treatment, the patients with low CA125 levels at baseline that remained low during treatment had the best clinical outcome (a median survival of 83 months and a progression-free survival of 34 months). In contrast, the patients with high CA125 values at baseline with a modest decrease during treatment had the highest risk of death and progression (hazard ratio [95% confidence interval]: 4.83 [3.56, 6.54] for overall survival and 5.15 [3.87, 6.87] for progression-free survival). Conclusions: Longitudinal trajectories of CA125 may provide more direct information for the prognoses of patients with advanced ovarian cancer undergoing chemotherapy treatment.
- 7 July 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (7) , 390
Open AccessTrajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical Trial
Background: A single measurement or a summary of a limited number of measurements of CA125 was considered in the prediction of clinical outcomes for patients with ovarian cancer. We aimed to identify the classes of patients with advanced ovarian cancer based on their CA125 trajectory and to investigate the heterogeneity of clinical outcomes among the patients in the different classes. Methods: CA125 trajectory classes were identified by latent-class mixed models based on values collected within 3 and 6 months post-treatment for 819 women with advanced ovarian cancer enrolled in a randomized trial. Results: Based on their CA125 values during the first 6 months of treatment, the patients with low CA125 levels at baseline that remained low during treatment had the best clinical outcome (a median survival of 83 months and a progression-free survival of 34 months). In contrast, the patients with high CA125 values at baseline with a modest decrease during treatment had the highest risk of death and progression (hazard ratio [95% confidence interval]: 4.83 [3.56, 6.54] for overall survival and 5.15 [3.87, 6.87] for progression-free survival). Conclusions: Longitudinal trajectories of CA125 may provide more direct information for the prognoses of patients with advanced ovarian cancer undergoing chemotherapy treatment.
- 19 October 2024
- Published by Elsevier in Preventive Medicine
- Vol. 189, 108153
Association between self-reported child maltreatment and risk of hospital-treated infectious diseases in middle-aged and older adults: A UK Biobank cohort study
- 19 October 2024
- Published by Elsevier in Preventive Medicine
- Vol. 189, 108153
Association between self-reported child maltreatment and risk of hospital-treated infectious diseases in middle-aged and older adults: A UK Biobank cohort study
- 8 February 2024
- Published by Elsevier in Diabetes & Metabolism
- Vol. 50 (2) , 101523
High serum total bilirubin as a potential protective factor for gestational diabetes mellitus: A retrospective cohort study of 92,885 Chinese pregnant women
- 8 February 2024
- Published by Elsevier in Diabetes & Metabolism
- Vol. 50 (2) , 101523
High serum total bilirubin as a potential protective factor for gestational diabetes mellitus: A retrospective cohort study of 92,885 Chinese pregnant women
- Open Access
- 1 December 2023
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 15, 1159-1170
Age-Dependent Association Between Body Mass Index and All-Cause Mortality Among Patients with Hypertension: A Longitudinal Population-Based Cohort Study in China
Purpose: The association between body mass index (BMI) and all-cause mortality may vary among hypertensive patients of different ages. This study aimed to investigate the age-dependent association between BMI and all-cause mortality among patients with hypertension. Patients and Methods: A total of 212,394 participants with hypertension aged 20– 85 years from Minhang Hypertension Standardization Management System in Shanghai of China were included. Follow-up began at the time when individuals were first recorded and ended at death, loss to follow-up, or December 31, 2018, whichever came first. Additive Cox proportional hazards models with thin plate smoothing functions and conventional Cox proportional hazards models were adopted to examine the relationship between BMI, age, and mortality. The joint effect of BMI and age on mortality was assessed using a bivariate response model. Results: We found that the BMI–mortality relationship followed a U-shaped pattern, with a trough at 26– 27 kg/m2. Compared with normal weight, underweight was associated with a 50% increased risk of premature mortality (hazard ratio 1.50, 95% confidence interval 1.43 to 1.57). Whereas among those aged 45– 59 and 60– 85 years, overweight was associated with 13% (0.87, 0.80 to 0.94) and 18% (0.82, 0.80 to 0.84) reduction in risk of death, respectively. Bivariate response model indicated a significant interaction between BMI and age (P < 0.05). Among younger and older patients, we found a descending trend for mortality risk, with BMI increasing at different age levels, whereas a reverse J-shaped relation pattern was observed among middle-aged patients. Conclusion: The impact of BMI on all-cause mortality in hypertensive patients varies with age, and moderate weight gain may benefit longevity in middle-aged and older patients.
- 1 December 2023
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 15, 1159-1170
Open AccessAge-Dependent Association Between Body Mass Index and All-Cause Mortality Among Patients with Hypertension: A Longitudinal Population-Based Cohort Study in China
Purpose: The association between body mass index (BMI) and all-cause mortality may vary among hypertensive patients of different ages. This study aimed to investigate the age-dependent association between BMI and all-cause mortality among patients with hypertension. Patients and Methods: A total of 212,394 participants with hypertension aged 20– 85 years from Minhang Hypertension Standardization Management System in Shanghai of China were included. Follow-up began at the time when individuals were first recorded and ended at death, loss to follow-up, or December 31, 2018, whichever came first. Additive Cox proportional hazards models with thin plate smoothing functions and conventional Cox proportional hazards models were adopted to examine the relationship between BMI, age, and mortality. The joint effect of BMI and age on mortality was assessed using a bivariate response model. Results: We found that the BMI–mortality relationship followed a U-shaped pattern, with a trough at 26– 27 kg/m2. Compared with normal weight, underweight was associated with a 50% increased risk of premature mortality (hazard ratio 1.50, 95% confidence interval 1.43 to 1.57). Whereas among those aged 45– 59 and 60– 85 years, overweight was associated with 13% (0.87, 0.80 to 0.94) and 18% (0.82, 0.80 to 0.84) reduction in risk of death, respectively. Bivariate response model indicated a significant interaction between BMI and age (P < 0.05). Among younger and older patients, we found a descending trend for mortality risk, with BMI increasing at different age levels, whereas a reverse J-shaped relation pattern was observed among middle-aged patients. Conclusion: The impact of BMI on all-cause mortality in hypertensive patients varies with age, and moderate weight gain may benefit longevity in middle-aged and older patients.
- Open Access
- 18 October 2023
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 30 (4)
Eomesodermin expression in CD4+T‐cells associated with disease progression in amyotrophic lateral sclerosis
Aim: To clarify the role of Eomesodermin (EOMES) to serve as a disease‐relevant biomarker and the intracellular molecules underlying the immunophenotype shifting of CD4+T subsets in amyotrophic lateral sclerosis (ALS).Methods: The derivation and validation cohorts included a total of 148 ALS patients and 101 healthy controls (HCs). Clinical data and peripheral blood were collected. T‐cell subsets and the EOMES expression were quantified using multicolor flow cytometry. Serum neurofilament light chain (NFL) was measured. In 1‐year longitudinal follow‐ups, the ALSFRS‐R scores and primary endpoint events were further recorded in the ALS patients of the validation cohort.Results: In the derivation cohort, the CD4+EOMES+T‐cell subsets were significantly increased (p < 0.001). EOMES+ subset was positively correlated with increased serum NFL levels in patients with onset longer than 12 months. In the validation cohort, the elevated CD4+EOMES+T‐cell proportions and their association with NFL levels were also identified. The longitudinal study revealed that ALS patients with higher EOMES expression were associated with higher progression rates (p = .010) and worse prognosis (p = .003).Conclusions: We demonstrated that increased CD4+EOMES+T‐cell subsets in ALS were associated with disease progression and poor prognosis. Identifying these associations may contribute to a better understanding of the immunopathological mechanism of ALS.
- 18 October 2023
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 30 (4)
Open AccessEomesodermin expression in CD4+T‐cells associated with disease progression in amyotrophic lateral sclerosis
Aim: To clarify the role of Eomesodermin (EOMES) to serve as a disease‐relevant biomarker and the intracellular molecules underlying the immunophenotype shifting of CD4+T subsets in amyotrophic lateral sclerosis (ALS).Methods: The derivation and validation cohorts included a total of 148 ALS patients and 101 healthy controls (HCs). Clinical data and peripheral blood were collected. T‐cell subsets and the EOMES expression were quantified using multicolor flow cytometry. Serum neurofilament light chain (NFL) was measured. In 1‐year longitudinal follow‐ups, the ALSFRS‐R scores and primary endpoint events were further recorded in the ALS patients of the validation cohort.Results: In the derivation cohort, the CD4+EOMES+T‐cell subsets were significantly increased (p < 0.001). EOMES+ subset was positively correlated with increased serum NFL levels in patients with onset longer than 12 months. In the validation cohort, the elevated CD4+EOMES+T‐cell proportions and their association with NFL levels were also identified. The longitudinal study revealed that ALS patients with higher EOMES expression were associated with higher progression rates (p = .010) and worse prognosis (p = .003).Conclusions: We demonstrated that increased CD4+EOMES+T‐cell subsets in ALS were associated with disease progression and poor prognosis. Identifying these associations may contribute to a better understanding of the immunopathological mechanism of ALS.
- Open Access
- 19 May 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 875489
Risk Prediction of Second Primary Malignancies in Primary Early-Stage Ovarian Cancer Survivors: A SEER-Based National Population-Based Cohort Study
Purpose: This study aimed to characterize the clinical features of early-stage ovarian cancer (OC) survivors with second primary malignancies (SPMs) and provided a prediction tool for individualized risk of developing SPMs.Methods: Data were obtained from the Surveillance, Epidemiology and End Results (SEER) database during 1998–2013. Considering non-SPM death as a competing event, the Fine and Gray model and the corresponding nomogram were used to identify the risk factors for SPMs and predict the SPM probabilities after the initial OC diagnosis. The decision curve analysis (DCA) was performed to evaluate the clinical utility of our proposed model.Results: A total of 14,314 qualified patients were enrolled. The diagnosis rate and the cumulative incidence of SPMs were 7.9% and 13.6% [95% confidence interval (CI) = 13.5% to 13.6%], respectively, during the median follow-up of 8.6 years. The multivariable competing risk analysis suggested that older age at initial cancer diagnosis, white race, epithelial histologic subtypes of OC (serous, endometrioid, mucinous, and Brenner tumor), number of lymph nodes examined (<12), and radiotherapy were significantly associated with an elevated SPM risk. The DCA revealed that the net benefit obtained by our proposed model was higher than the all-screening or no-screening scenarios within a wide range of risk thresholds (1% to 23%).Conclusion: The competing risk nomogram can be potentially helpful for assisting physicians in identifying patients with different risks of SPMs and scheduling risk-adapted clinical management. More comprehensive data on treatment regimens and patient characteristics may help improve the predictability of the risk model for SPMs.
- 19 May 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 875489
Open AccessRisk Prediction of Second Primary Malignancies in Primary Early-Stage Ovarian Cancer Survivors: A SEER-Based National Population-Based Cohort Study
Purpose: This study aimed to characterize the clinical features of early-stage ovarian cancer (OC) survivors with second primary malignancies (SPMs) and provided a prediction tool for individualized risk of developing SPMs.Methods: Data were obtained from the Surveillance, Epidemiology and End Results (SEER) database during 1998–2013. Considering non-SPM death as a competing event, the Fine and Gray model and the corresponding nomogram were used to identify the risk factors for SPMs and predict the SPM probabilities after the initial OC diagnosis. The decision curve analysis (DCA) was performed to evaluate the clinical utility of our proposed model.Results: A total of 14,314 qualified patients were enrolled. The diagnosis rate and the cumulative incidence of SPMs were 7.9% and 13.6% [95% confidence interval (CI) = 13.5% to 13.6%], respectively, during the median follow-up of 8.6 years. The multivariable competing risk analysis suggested that older age at initial cancer diagnosis, white race, epithelial histologic subtypes of OC (serous, endometrioid, mucinous, and Brenner tumor), number of lymph nodes examined (<12), and radiotherapy were significantly associated with an elevated SPM risk. The DCA revealed that the net benefit obtained by our proposed model was higher than the all-screening or no-screening scenarios within a wide range of risk thresholds (1% to 23%).Conclusion: The competing risk nomogram can be potentially helpful for assisting physicians in identifying patients with different risks of SPMs and scheduling risk-adapted clinical management. More comprehensive data on treatment regimens and patient characteristics may help improve the predictability of the risk model for SPMs.